/C O R R E C T I O N -- Roche/
MWN-AI** Summary
Roche has officially launched the cobas® eplex respiratory pathogen panel 3 (RP3), a significant advancement in diagnostic testing for respiratory infections. This comprehensive test, available in CE-mark accepting countries, is designed to detect up to 25 different viral and bacterial pathogens, including well-known threats such as SARS-CoV-2 and influenza. The RP3 panel is tailored to assist clinicians in swiftly and accurately identifying respiratory infections, which is particularly critical for high-risk patient groups, such as the elderly and immunocompromised individuals.
The cobas eplex RP3 aims to streamline the diagnostic process by reducing the complexity often associated with differentiating between various respiratory pathogens that yield similar symptoms. The test prides itself on rapid result delivery, potentially enabling healthcare providers to make informed treatment decisions much faster, which could significantly enhance patient outcomes in urgent care settings.
With an impressive turnaround time that requires less than one minute of hands-on preparation, this panel can be seamlessly integrated into hospital workflows. Moreover, its design allows for operation around the clock, proving especially beneficial during peak respiratory seasons when hospitals are strained with cases.
Crucially, the RP3 panel not only aids in diagnosis and subsequent treatment but also assists in infection control measures, potentially reducing unnecessary antibiotic usage. Noteworthy features include customizable testing options based on local epidemiology and updates to include emerging bacterial pathogens. Roche continues to build on its legacy as a leading healthcare company, focusing on providing solutions that meet the evolving needs of patients and healthcare professionals globally.
MWN-AI** Analysis
Roche (SIX: RO; OTCQX: RHHBY) has recently launched the cobas eplex respiratory pathogen panel 3 (RP3), which is set to enhance diagnostic capabilities in respiratory infections significantly. This innovative technology can detect up to 25 viruses and bacteria, including critical pathogens such as SARS-CoV-2 and influenza, in a single sample, allowing for rapid and targeted treatment.
From a market analysis perspective, Roche's entry into this particular niche occurs at a pivotal time, especially as respiratory illnesses typically surge during colder months. The demand for quick and accurate testing is likely to escalate, particularly within high-risk populations, suggesting that Roche's new rollout could not only improve patient outcomes but also present substantial commercial opportunities.
Financially, Roche has consistently demonstrated robust performance, bolstered by its strong pipeline of diagnostic tools and therapeutics. The cobas eplex RP3 enhances the company's existing offerings and positions it strategically to capture market share as healthcare providers increasingly invest in technologies that improve patient care while managing operational costs. Furthermore, the simplified workflow and reduced time to results (less than a minute of hands-on time) can streamline laboratory operations, potentially leading to higher throughput and increased revenue.
Investors may want to watch how Roche capitalizes on this new launch. The company’s commitment to addressing urgent healthcare needs reflects a proactive stance that can resonate positively with stakeholders. Additionally, any positive reception from the medical community could lead to broader adoption and increased sales, bolstering Roche’s already strong financial standing.
Overall, Roche seems well-positioned for continued growth, particularly in diagnostics. Current shareholders can maintain confidence, while new investors might see potential in Roche’s innovation-driven strategy within the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
In the news release, Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets, issued 24-Mar-2026 by Roche over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Roche launches the cobas eplex respiratory pathogen panel 3, a fast and comprehensive test to help clinicians treat patients with respiratory infections, in CE markets
- The new test detects up to 25 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample.
- Rapid results enable doctors to make fast, confident and critical treatment decisions that are vital for high-risk patients.
- Designed for the cobas eplex system, the test is easy to use and available around the clock, helping hospitals manage surges in respiratory cases.
PLEASANTON, Calif., March 24, 2026 /PRNewswire/ -- Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spectrum of viruses and bacteria that cause respiratory illness. The test is now available in countries accepting the CE mark.
Differential diagnosis of respiratory infections can be complex because many of the viruses and bacteria associated with respiratory infections may cause very similar symptoms. For vulnerable populations, including the elderly, young children, and those with weakened immune systems, a respiratory infection can quickly become life-threatening.
"In respiratory care, time is everything. Knowing exactly what is making a patient sick allows clinicians to make fast, effective decisions that can save lives," said Josh Lauer, Global Head of Molecular Labs at Roche Diagnostics. "We are providing hospitals with a powerful tool to manage the complexity of respiratory infections, ensuring that patients — especially those at high risk — get the targeted care they need without delay."
The cobas eplex RP3 panel provides critical support to healthcare providers during peak respiratory seasons, which are the most demanding times of the year. The new test detects more than 20 different viral and bacterial pathogens simultaneously. This helps clinicians quickly pinpoint the exact cause of a patient's illness, allowing them to start the right treatment sooner, implement adequate infection and transmission control measures, and, in some cases, avoid unnecessary antibiotic use and improve patient prognosis.
With less than one minute of hands-on time required to start the test, it is incredibly easy for laboratory staff to use. With ease of use and fast time to results, the cobas eplex RP3 panel can help reduce the time patients spend in the emergency room and allows hospitals to better manage isolation beds, keeping infectious patients separate from others.
About the cobas eplex RP3 Panel
The cobas eplex respiratory pathogen panel 3 is a qualitative in vitro diagnostic test aimed at the simultaneous detection and differentiation of up to 25 viral and bacterial targets. It runs on the cobas eplex system, a platform designed to simplify laboratory workflow with features like automated result reporting and external control tracking & monitoring. Like the RP2 panel, the RP3 panel detects common pathogens, such as influenza virus A and B, RSV, SARS-CoV-2,, plus new pathogens including Bordetella parapertussis and Chlamydia pneumoniae that can cause severe illness in high risk patients. The cobas eplex RP3 panel also has updated inclusivity for influenza virus and SARS-CoV-2 to ensure coverage of current and recently circulating strains. This test is also the first in the cobas eplex family to feature flexible syndromic testing, giving the option to labs to customise up to 5 distinct panels based on local prevalence needs or unique patient presentations.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
For further information please contact
Yvette Petillon, Group Media Relations
Phone: +41 79 961 92 50
e-Mail: yvette.petillon@roche.com
Brien Mahoney, Molecular Labs Communications
Phone: +1 925 699 8512
e-Mail: brien.mahoney@roche.com
Correction: The stated number of detectable viruses and bacteria has been corrected from 250 to 25 in the sub-headline.
SOURCE Roche
FAQ**
How does Roche Holding Ltd ADR RHHBY plan to leverage the new cobas eplex RP3 panel to address the growing demand for rapid testing in respiratory infection diagnosis, particularly during peak seasons?
What competitive advantages does Roche Holding Ltd ADR RHHBY believe the cobas eplex RP3 panel offers compared to other respiratory diagnostic tests currently available in the market?
In light of recent developments, how will Roche Holding Ltd ADR RHHBY manage production and distribution to meet the anticipated demand for the cobas eplex RP3 panel across various CE markets?
What are the expected financial impacts and market opportunities for Roche Holding Ltd ADR RHHBY following the launch of the cobas eplex RP3 panel, especially regarding its integration within hospitals' existing workflows?
**MWN-AI FAQ is based on asking OpenAI questions about Roche Holding Ltd ADR (OTC: RHHBY).
NASDAQ: RHHBY
RHHBY Trading
-0.55% G/L:
$48.96 Last:
646,450 Volume:
$49.05 Open:
